Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register

@inproceedings{Humphries2018CoronaryHD,
  title={Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register},
  author={S. E. Humphries and J. A. Cooper and Mike T. M. Seed and Nigel K. Capps and P. N. Durrington and Ben J Jones and I.F.W. McDowell and Haluk Soran and H.A.W. Neil},
  booktitle={Atherosclerosis},
  year={2018}
}
BACKGROUND AND AIMS Patients with familial hypercholesterolaemia (FH) have an elevated risk of coronary heart disease (CHD). Here we compare changes in CHD mortality in patients with heterozygous (FH) pre 1992, before lipid-lowering therapy with statins was used routinely, and in the periods 1992-2008 and 2008-2016. METHODS 1903 Definite (DFH) and 1650 Possible (PFH) patients (51% women) aged 20-79 years, recruited from 21 lipid clinics in the United Kingdom and followed prospectively between… CONTINUE READING
BETA
18
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Scientific Steering Committee on behalf of the Simon Broome Register Group - mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management, Athereosclerosis

D. J. Betteridge, K. Broome, P. N. Durrington
  • 1999
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Scientific Steering Committee on behalf of the Simon Broome Register Group: the risk of fatal coronary heart disease in familial hypercholesterolaemia

The Simon Broome Register Group
  • BMC Med. J
  • 1991
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…